# Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants

> **NCT02027337** · PHASE4 · UNKNOWN · sponsor: **Tyumen State Medical Academy** · enrollment: 200 (estimated)

## Conditions studied

- Polycystic Ovarian Syndrome
- Hyperandrogenism
- Menstrual Irregularities

## Interventions

- **DRUG:** 20 mcg ethinylestradiol /3 mg drospirenone
- **DRUG:** 20 mcg ethinylestradiol/3 mg drospirenone and Selmevit
- **DRUG:** 30 mcg ethinylestradiol/3 mg drospirenone
- **DRUG:** 30 mcg ethinylestradiol/3 mg drospirenone and Selmevit
- **DRUG:** 35 mcg ethinylestradiol/2 mg cyproterone
- **DRUG:** 35 mcg ethinylestradiol/2 mg cyproterone and Selmevit

## Key facts

- **NCT ID:** NCT02027337
- **Lead sponsor:** Tyumen State Medical Academy
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2015-03
- **Final completion:** 2015-10
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2014-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02027337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02027337, "Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT02027337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*